Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype a infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 1, 2012, Pages 9-18

  Eller, Michael A ^a,b   Eller, Leigh Anne ^a   Ratto Kim, Silvia ^a   Ouma, Benson J ^c   Lo, Vicky ^a   De Souza, Mark ^d   Guwatudde, David ^c,e   Nails, Barbara ^a   Michael, Nelson L ^a   Wabwire Mangen, Fred ^c,e   Robb, Merlin L ^a   Marovich, Mary A ^a   Sandberg, Johan K ^b   Currier, Jeffrey R ^a  

^a US Military HIV Research Program   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Makerere University   (Uganda)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

Author keywords

AIDS; HIV 1; memory; T cells; viral infections

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MIDOSTAURIN; NEF PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VARIANT INCLUSIVE PEPTIDE; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DEGRANULATION; EOSINOPHILIA; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MALE; NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; SYPHILIS; TREATMENT OUTCOME; UGANDA; VIRUS LOAD;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL4; CHRONIC DISEASE; CYTOMEGALOVIRUS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 84865789584     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825c1217     Document Type: Article

References (48)

1. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8: 247-258.
2. Taylor BS, Sobieszczyk ME, McCutchan FE, et al. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008;358:1590-1602.
3. Peeters M, Toure-Kane C, Nkengasong JN. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS. 2003;17:2547-2560.
4. Harris ME, Serwadda D, Sewankambo N, et al. Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses. 2002;18:1281-1290.
5. Arroyo MA, Sateren WB, Serwadda D, et al. Higher HIV-1 incidence and genetic complexity along main roads in Rakai District, Uganda. J Acquir Immune Defic Syndr. 2006;43:440-445.
6. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis. 2007;195:1177-1180.
7. Kanki PJ, Hamel DJ, Sankale JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis. 1999;179:68-73.
8. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008;197:707-713.
9. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis. 2002; 185:1244-1250.
10. Conroy SA, Laeyendecker O, Redd AD, et al. Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002. AIDS Res Hum Retroviruses. 2010;26:1087-1091.
11. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68: 4650-4655.
12. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103-6110.
13. Musey L, Hughes J, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med. 1997;337:1267-1274.
14. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009;206:1253-1272.
15. +) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-998.
16. Matano T, Shibata R, Siemon C, et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol. 1998;72:164-169.
17. + lymphocytes. Science. 1999; 283:857-860.
18. + T cells. Blood. 2006;107: 4781-4789.
19. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13:46-53.
20. Geldmacher C, Currier JR, Herrmann E, et al. CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol. 2007;81:2440-2448.
21. + T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
22. Ratto-Kim S, Garner RP, Kim JH, et al. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort. J Infect Dis. 2004;189:1988-1995.
23. Harari A, Petitpierre S, Vallelian F, et al. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood. 2004;103:966-972.
24. + T-cell response in different phases of HIV infection. AIDS. 2010;24:947-957.
25. + cells with different requirements for activation and differentiation. J Immunol. 1991;146: 2088-2094.
26. + effector and memory T cell generation. Nat Immunol. 2003;4:835-842.
27. Sallusto F, Lenig D, Förster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
28. Lefrancois L, Marzo AL. The descent of memory T-cell subsets. Nat Rev Immunol. 2006;6:618-623.
29. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106-111.
30. Guwatudde D, Wabwire-Mangen F, Eller LA, et al. Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda. PLoS ONE. 2009;4:e4145.
31. Olemukan RE, Eller LA, Ouma BJ, et al. Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting. Clin Vaccine Immunol. 2010;17: 910-918.
32. Eller LA, Eller MA, Ouma BJ, et al. Large-scale human immunodeficiency virus rapid test evaluation in a low-prevalence Ugandan blood bank population. J Clin Microbiol. 2007;45:3281-3285.
33. Jabbari A, Harty JT. Simultaneous assessment of antigen-stimulated cytokine production and memory subset composition of memory CD8 T cells. J Immunol Methods. 2006;313:161-168.
34. Currier JR, Ngauy V, de Souza MS, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS ONE. 2010;5:e13983.
35. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A. 2011;79: 167-174.
36. Badenhorst CJ, Fourie J, Steyn K, et al. The haematological profile of urban black Africans aged 15-64 years in the Cape Peninsula. East Afr Med J. 1995;72:19-24.
37. Eller LA, Eller MA, Ouma B, et al. Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. PLoS ONE. 2008;3:e3919.
38. Ezeilo GC. Non-genetic neutropenia in Africans. Lancet. 1972;2: 1003-1004.
39. Shaper AG, Lewis P. Genetic neutropenia in people of African origin. Lancet. 1971;2:1021-1023.
40. Pontesilli O, Carotenuto P, Kerkhof-Garde SR, et al. Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses. 1999;15:973-981.
41. + T cells are a consequence of antigen load. J Virol. 2007;81:2713-2725.
42. + T lymphocytes with cellular maturation. J Exp Med. 2006;203:2865-2877.
43. Kannanganat S, Ibegbu C, Chennareddi L, et al. Multiple-cytokine- producing antiviral CD4 T cells are functionally superior to single-cytokineproducing cells. J Virol. 2007;81:8468-8476.
44. +) T-cell clones. J Virol. 2001;75:9771-9779.
45. + T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci USA. 2009;106:9791-9796.
46. Geldmacher C, Ngwenyama N, Schuetz A, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med. 2010;207:2869-2881.
47. + T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog. 2010;6:e1000780.
48. + T-cell responses. J Virol. 2010;84:11020-11029.